Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pexidartinib + VIP152 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pexidartinib | Turalio | PLX3397|CML-261 | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 | Turalio (pexidartinib) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190). Turalio (pexidartinib) is FDA approved for use in patients with symptomatic tenosynovial giant cell tumor (FDA.gov). |
VIP152 | BAY 1251152|BAY1251152|BAY-1251152|VIP-152 | CDK9 Inhibitor 21 | VIP152 (BAY 1251152) selectively inhibits CDK9, potentially resulting in antitumor activity (PMID: 35046056, PMID: 32488087). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|